Host: |
Mouse |
Applications: |
WB/ELISA |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Mouse monoclonal antibody anti-Cyclin-dependent kinase 4 inhibitor B (50-138) is suitable for use in Western Blot and ELISA research applications. |
Clonality: |
Monoclonal |
Clone ID: |
PTR2192 |
Conjugation: |
Unconjugated |
Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
Purification: |
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. |
Concentration: |
1 mg/mL |
Dilution Range: |
WB 1:500-2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
CDKN2B |
Gene ID: |
1030 |
Uniprot ID: |
CDN2B_HUMAN |
Immunogen Region: |
50-138 |
Specificity: |
This antibody detects endogenous levels of p15 INK (PTR2192) at Human. The antibody was also Predict react with Mouse;Rat |
Immunogen: |
Synthesized peptide derived from human p15 INK (PTR2192) AA range: 50-138 |
Tissue Specificity | Isoform 2 is expressed in normal (keratinocytes, fibroblasts) and tumor cell lines. |
Function | Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. |
Protein Name | Cyclin-Dependent Kinase 4 Inhibitor BMultiple Tumor Suppressor 2Mts-2P14-Ink4bP15-Ink4bP15ink4b |
Database Links | Reactome: R-HSA-2173796Reactome: R-HSA-2559580Reactome: R-HSA-2559582Reactome: R-HSA-2559585Reactome: R-HSA-69231 |
Cellular Localisation | CytoplasmAlso Found In The Nucleus |
Alternative Antibody Names | Anti-Cyclin-Dependent Kinase 4 Inhibitor B antibodyAnti-Multiple Tumor Suppressor 2 antibodyAnti-Mts-2 antibodyAnti-P14-Ink4b antibodyAnti-P15-Ink4b antibodyAnti-P15ink4b antibodyAnti-CDKN2B antibodyAnti-MTS2 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance